SA-Q1 - komunikat spółki KRKA, TOVARNA ZDRAVIL D.D. (krka) - komunikat ESPI

Komunikat spółki

COMMON REPORT

	POLISH FINANCIAL SUPERVISION AUTHORITY
				UNI - EN REPORT No		26	/	2025
	Date of issue:		2025-05-15
	Short name of the issuer
	KRKA
	Subject
	Unaudited Interim Report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2025
	Official market - legal basis
	art. 56. 1. 2 of Act on Public Offering.
	Unofficial market - legal basis
	Contents of the report:
	Based on Article 26 of the Rules of the Ljubljana Stock Exchange d.d. company Krka, d. d., Novo mesto publishes the Unaudited interim Report of the Krka Group and Krka, d. d., Novo mesto for the first quarter of 2025. The report will be published on the Company's website (www.krka.biz) from 15 May 2025 onwards, for a minimum period of 5 years.
	Annexes
	File				Description
	Q1 2025 Unaudited Interim Report of the Krka Group and Krka Company.pdf				Q1 2025 Unaudited Interim Report of the Krka Group and Krka Company
	Press Release.pdf				Press Release

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification of the WSE in Warsow)

8501

Nove Mesto

(post code)

(city)

Smarjeska

6

(street)

(number)

+386 7 331 21 11

+386 7 332 15 37

(phone number)

(fax)

(e-mail)

(web site)

nie dotyczy

(NIP)

(REGON)

	SIGNATURE OF PERSONS REPRESENTING THE COMPANY
	Date	Name	Position / Function	Signature
	2025-05-15	Jože Colarič	President of the Management Board and CEO

Nazwa jednostki:	KRKA, TOVARNA ZDRAVIL D.D.
Nazwa skrócona jednoskti:	KRKA
Adres:	Smarjeska 6, 8501 Nove Mesto
Telefon:	+386 7 331 21 11
Fax:	+386 7 332 15 37
NIP:	nie dotyczy